{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T18:56:58Z","timestamp":1776193018084,"version":"3.50.1"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Rare disease clinical trials are constrained to small sample sizes and may lack placebo-control, leading to challenges in drug development. This paper proposes a Bayesian model-based framework for early go\/no-go decision making in rare disease drug development, using Duchenne muscular dystrophy (DMD) as an example. Early go\/no-go decisions were based on projections of long-term functional outcomes from a Bayesian model-based analysis of short-term trial data informed by prior knowledge based on 6MWT natural history literature data in DMD patients. Frequentist hypothesis tests were also applied as a reference analysis method. A number of combinations of hypothetical trial designs, drug effects and cohort comparison methods were assessed. The proposed Bayesian model-based framework was superior to the frequentist method for making go\/no-go decisions across all trial designs and cohort comparison methods in DMD. The average decision accuracy rates across all trial designs for the Bayesian and frequentist analysis methods were 45.8 and 8.98%, respectively. A decision accuracy rate of at least 50% was achieved for 42 and 7% of the trial designs under the Bayesian and frequentist analysis methods, respectively. The frequentist method was limited to the short-term trial data only, while the Bayesian methods were informed with both the short-term data and prior information. The specific results of the DMD case study were limited due to incomplete specification of individual-specific covariates in the natural history literature data and should be reevaluated using a full natural history dataset. These limitations aside, the framework presented provides a proof of concept for the utility of Bayesian model-based methods for decision making in rare disease trials.<\/jats:p>","DOI":"10.1371\/journal.pone.0247286","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T18:06:26Z","timestamp":1651169186000},"page":"e0247286","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Bayesian modeling and simulation to inform rare disease drug development early decision-making: Application to Duchenne muscular dystrophy"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6084-7172","authenticated-orcid":true,"given":"Janelle L.","family":"Lennie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John T.","family":"Mondick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc R.","family":"Gastonguay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"key":"pone.0247286.ref001","unstructured":"RARE Facts; 2021. Available from: https:\/\/globalgenes.org\/."},{"issue":"1","key":"pone.0247286.ref002","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41436-019-0616-9","article-title":"Developing interactions with industry in rare diseases: lessons learned and continuing challenges","volume":"22","author":"SA Berry","year":"2020","journal-title":"Genet Med"},{"key":"pone.0247286.ref003","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13023-014-0170-0","article-title":"A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov","volume":"9","author":"SA Bell","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"pone.0247286.ref004","unstructured":"Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Rare Diseases: Common Issues in Drug Development Guidance for Industry. U.S. Food and Drug Administration; 2019."},{"key":"pone.0247286.ref005","unstructured":"FDA Adequate and well-controlled studies.; 21 C.F.R. \u00a7314.126 (2021)."},{"issue":"5","key":"pone.0247286.ref006","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/pst.1870","article-title":"Decision-making in drug development using a composite definition of success","volume":"17","author":"G Saint-Hilary","year":"2018","journal-title":"Pharm Stat"},{"issue":"5","key":"pone.0247286.ref007","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/sim.1429","article-title":"Stopping clinical trials because of treatment ineffectiveness: a comparison of a futility design with a method of stochastic curtailment","volume":"22","author":"J Whitehead","year":"2003","journal-title":"Stat Med"},{"issue":"3","key":"pone.0247286.ref008","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/pst.1746","article-title":"Decision-making in early clinical drug development","volume":"15","author":"P Frewer","year":"2016","journal-title":"Pharm Stat"},{"issue":"1","key":"pone.0247286.ref009","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management","volume":"9","author":"K Bushby","year":"2010","journal-title":"Lancet Neurol"},{"issue":"6","key":"pone.0247286.ref010","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/mus.21808","article-title":"The 6-minute walk test in Duchenne\/Becker muscular dystrophy: longitudinal observations","volume":"42","author":"CM McDonald","year":"2010","journal-title":"Muscle Nerve"},{"issue":"4","key":"pone.0247286.ref011","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.24332","article-title":"Ataluren treatment of patients with nonsense mutation dystrophinopathy","volume":"50","author":"K Bushby","year":"2014","journal-title":"Muscle Nerve"},{"issue":"3","key":"pone.0247286.ref012","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/mus.23905","article-title":"The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study","volume":"48","author":"CM McDonald","year":"2013","journal-title":"Muscle Nerve"},{"issue":"5","key":"pone.0247286.ref013","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"JR Mendell","year":"2013","journal-title":"Ann Neurol"},{"issue":"8","key":"pone.0247286.ref014","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial","volume":"77","author":"PR Clemens","year":"2020","journal-title":"JAMA Neurol"},{"key":"pone.0247286.ref015","unstructured":"FDA. FDA grants accelerated approval to first drug for Duchenne muscular dystrophy; 2016. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-first-drug-duchenne-muscular-dystrophy."},{"key":"pone.0247286.ref016","unstructured":"Center for Drug Evaluation and Research. Eteplirsen Summary Review. U.S Food and Drug Administration; 2016. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/206488_summary%20review_redacted.pdf."},{"issue":"21","key":"pone.0247286.ref017","doi-asserted-by":"crossref","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"DE Frank","year":"2020","journal-title":"Neurology"},{"key":"pone.0247286.ref018","unstructured":"Hoffman E. Variable DystrophinContent within Myofibers, between Myofibers, and between Regions of Muscles: Determining the Level of Dystrophinthat makes a Clinical Impact in BMD and Manifesting Carriers of DMD; 2016. Presentation. Available from: https:\/\/www.fda.gov\/media\/92016\/download."},{"issue":"1","key":"pone.0247286.ref019","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10928-020-09671-7","article-title":"Latent process model of the 6-minute walk test in Duchenne muscular dystrophy: A Bayesian approach to quantifying rare disease progression","volume":"47","author":"JL Lennie","year":"2020","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"pone.0247286.ref020","first-page":"S84","article-title":"Simulation from ODE-based population PK\/PD and systems pharmacology models in R with mrgsolve","volume":"42","author":"KT Baron","year":"2015","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"pone.0247286.ref021","first-page":"175","article-title":"Is 30 the magic number? Issues in sample size estimation","volume":"4","author":"SS Kar","year":"2013","journal-title":"National Journal of Community Medicine"},{"key":"pone.0247286.ref022","volume-title":"Nonparametric Statistics for Non-Statisticians: A Step-by-Step Approach","author":"W Gregory","year":"2014"},{"key":"pone.0247286.ref023","volume-title":"Applied Statistics: From Bivariate Through Multivariate Techniques 2nd Edition","author":"RM Warner","year":"2007"},{"key":"pone.0247286.ref024","volume-title":"NONMEM Users Guide: Part I-VII","author":"SL Beal","year":"2018-2020"},{"key":"pone.0247286.ref025","volume-title":"Bayesian Data Analysis (Chapman & Hall\/CRC Texts in Statistical Science)","author":"A Gelman","year":"2013"},{"issue":"3","key":"pone.0247286.ref026","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1208\/aapsj060319","article-title":"The back-step method\u2013method for obtaining unbiased population parameter estimates for ordered categorical data","volume":"6","author":"MC Kjellsson","year":"2004","journal-title":"AAPS J"},{"issue":"12","key":"pone.0247286.ref027","doi-asserted-by":"crossref","first-page":"e115200","DOI":"10.1371\/journal.pone.0115200","article-title":"Age-related longitudinal changes in metabolic energy expenditure during walking in boys with Duchenne muscular dystrophy","volume":"9","author":"MA Brehm","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"pone.0247286.ref028","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.nmd.2013.05.006","article-title":"Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids","volume":"23","author":"N Goemans","year":"2013","journal-title":"Neuromuscul Disord"},{"issue":"9","key":"pone.0247286.ref029","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.nmd.2016.05.016","article-title":"Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy","volume":"26","author":"DMD Italian Group","year":"2016","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"pone.0247286.ref030","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/mus.23902","article-title":"The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study","volume":"48","author":"CM McDonald","year":"2013","journal-title":"Muscle Nerve"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0247286","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T20:27:40Z","timestamp":1700512060000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0247286"}},"subtitle":[],"editor":[{"given":"Gang","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0247286","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,28]]}}}